Connor, Clark & Lunn Investment Management (CC&L)
CLDX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Celldex Therapeutics CLDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.84M Buy
184,104
+65,899
+56% +$1.8M 0.01% 640
2025
Q4 		$3.21M Buy
+118,205
New +$3.11M 0.01% 792
2024
Q2 		– Sell
-8,158
Closed -$342K – 1418
2024
Q1 		$342K Sell
8,158
-20,380
-71% -$837K ﹤0.01% 1223
2023
Q4 		$1.13M Buy
28,538
+10,383
+57% +$305K 0.01% 828
2023
Q3 		$500K Buy
+18,155
New +$569K ﹤0.01% 1017
2023
Q2 		– Sell
-42,636
Closed -$1.53M – 1335
2023
Q1 		$1.53M Sell
42,636
-15,274
-26% -$659K 0.01% 616
2022
Q4 		$2.58M Sell
57,910
-22,740
-28% -$812K 0.01% 483
2022
Q3 		$2.27M Buy
+80,650
New +$2.47M 0.01% 472
2021
Q4 		– Sell
-12,117
Closed -$654K – 1093
2021
Q3 		$654K Sell
12,117
-2,416
-17% -$113K ﹤0.01% 719
2021
Q2 		$486K Buy
+14,533
New +$399K ﹤0.01% 795
2021
Q1 		– Sell
-37,346
Closed -$654K – 994
2020
Q4 		$654K Sell
37,346
-14,233
-28% -$256K ﹤0.01% 690
2020
Q3 		$765K Buy
+51,579
New +$604K 0.01% 672
2018
Q4 		– Sell
-51,337
Closed -$347K – 950
2018
Q3 		$347K Sell
51,337
-8,675
-14% -$60.7K ﹤0.01% 764
2018
Q2 		$453K Buy
60,012
+13,009
+28% +$174K ﹤0.01% 792
2018
Q1 		$1.64M Buy
47,003
+11,274
+32% +$437K 0.01% 412
2017
Q4 		$1.52M Sell
35,729
-79
-0.2% -$3.38K 0.01% 465
2017
Q3 		$1.54M Buy
35,808
+1,225
+4% +$45.9K 0.01% 462
2017
Q2 		$1.28M Buy
34,583
+29,010
+521% +$1.28M 0.01% 460
2017
Q1 		$302K Buy
+5,573
New +$290K ﹤0.01% 729
2015
Q2 		– Sell
-1,380
Closed -$577K – 621
2015
Q1 		$577K Sell
1,380
-293
-18% -$105K ﹤0.01% 376
2014
Q4 		$458K Buy
+1,673
New +$416K ﹤0.01% 400
2014
Q2 		– Sell
-7,840
Closed -$2.29M – 542
2014
Q1 		$2.29M Buy
7,840
+1,653
+27% +$633K 0.02% 260
2013
Q4 		$2.39M Sell
6,187
-73
-1% -$28.1K 0.02% 238
2013
Q3 		$3.42M Buy
6,260
+2,053
+49% +$704K 0.03% 143
2013
Q2 		$1.04M Buy
+4,207
New +$828K 0.01% 259

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CLDX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Celldex Therapeutics (CLDX) stake by 56% in Q1 2026, buying an estimated $1.8M and bringing the position to 184,104 shares worth $5.84M. The position accounts for 0.01% of the portfolio, ranked #640.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CLDX in Q2 2013 and has held it in 25 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 184,104 shares of Celldex Therapeutics worth $5.84M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 65,899 Celldex Therapeutics shares in Q1 2026, an estimated $1.8M.
  • Celldex Therapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #640 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 25 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.